What Is PNC-27? A p53/HDM-2 Membrane-Disrupting Research Peptide

PNC-27 is a synthetic peptide that fuses a p53–derived HDM-2–binding domain to a membrane-penetrating “leader” sequence. In published laboratory studies, it has been investigated for selectively inducing membrane disruption (necrosis) in cancer cells that express HDM-2 at their plasma membrane, while reportedly sparing normal cells in those same in-vitro models. PNC-27 is an experimental research compound. The information below summarizes preclinical, in-vitro and cell-line findings only. It is provided strictly for research and educational reference. PNC-27 is not a drug, not a treatment, and is not approved for human or veterinary use.

Research-use-only (RUO) note: nothing here describes a therapy, a clinical benefit, or any outcome in humans. All effects discussed were observed in cultured cells or laboratory models.

Quick facts

• Class: p53/HDM-2 membrane-disrupting (membranolytic) research peptide.
• Design: a chimeric peptide — a p53-derived HDM-2–binding segment joined to a membrane-residency / cell-penetrating “leader” sequence.
• Research focus: in-vitro investigation of cancer-cell-selective membrane disruption tied to HDM-2 localized at the cell membrane.
• Status: experimental; studied in cultured cells and laboratory models only. Not approved; not a treatment.
• Bolt Peptide does not sell PNC-27. This article is educational only.

What is PNC-27?

PNC-27 is a laboratory-synthesized chimeric peptide. One portion is derived from the tumor-suppressor protein p53 — specifically the region of p53 that binds HDM-2 (the human homolog of MDM-2), the protein cells use to regulate p53. The other portion is a membrane-penetrating leader sequence that allows the peptide to associate with and cross cell membranes. Because it joins a targeting domain to a membrane-active domain, researchers classify PNC-27 as a membranolytic, or membrane-disrupting, peptide rather than a conventional signaling peptide. In the literature it is described as an “anti-cancer” research peptide — terminology that refers to its behavior in cultured cancer cells, and does not imply any tested or approved use in people.

What does the research show?

Across cell-line studies, PNC-27 has been reported to bind HDM-2 in a conformation closely resembling the natural p53–HDM-2 interaction, and to trigger formation of transmembrane pores that lead to cancer-cell lysis. In one structural study using cancer cell lines and untransformed fibroblasts, electron microscopy with immunogold labeling visualized pores lined with PNC-27–HDM-2 complexes, and the peptide selectively lysed cancer-cell membranes while leaving the normal-cell controls intact (Sarafraz-Yazdi et al., 2022). Earlier work reported that PNC-27 kills cultured cancer cells — but not normal cells — by targeting HDM-2 specifically where it is present in the cell membrane (Michl, Pincus et al., 2010). A later mechanistic study in human pancreatic carcinoma cells additionally reported that, after engaging membrane-bound hdm-2, PNC-27 entered cells and associated with mitochondrial membranes, contributing to mitochondrial disruption (Krzesaj et al., 2024). Every one of these findings comes from in-vitro / cell-culture experiments. None demonstrates safety or effectiveness in humans.

Mechanisms studied in the lab

• HDM-2 membrane binding: the p53-derived domain binds HDM-2 located at the plasma membrane of cancer cells, anchoring the peptide where HDM-2 is exposed.
• Pore formation / necrosis: bound peptide–HDM-2 complexes are reported to assemble transmembrane pores, compromising membrane integrity and producing necrotic (rather than apoptotic) cell death in culture.
• Reported cancer-cell selectivity: in the cited models, normal cells that do not display HDM-2 at the membrane were not lysed — consistent with a membrane-HDM-2–dependent mechanism.

Research status

PNC-27 is an experimental research compound. Its characterization rests on in-vitro and cell-line work; the selectivity and mechanisms described above have been observed in laboratory systems, not in clinical use. PNC-27 is not approved by the FDA or any regulatory body, is not a medicine, and is not a cancer treatment. It is appropriate only for qualified in-vitro research conducted under proper institutional and safety oversight. Bolt Peptide does not sell PNC-27.

Related research compounds

Researchers exploring p53/HDM-2 biology and membrane-active peptides often review the broader landscape of research peptides. Browse the available research-use-only research peptide catalog. (PNC-27 itself is not part of the catalog and is covered here for educational purposes only.)

FAQ

Is PNC-27 a cancer treatment? No. PNC-27 is an experimental research peptide studied only in cultured cells and laboratory models. It is not approved, not a drug, and not a treatment for cancer or any other condition in humans or animals.

What makes PNC-27 different from other peptides? It is a chimeric design: a p53-derived HDM-2–binding domain fused to a membrane-penetrating sequence. Rather than acting as a signaling molecule, it has been studied for physically disrupting the membranes of cancer cells that present HDM-2 at the cell surface.

Does Bolt Peptide sell PNC-27? No. Bolt Peptide does not offer PNC-27. This article is purely educational. For research-use-only compounds we do carry, see the peptides catalog.

References

1. Sarafraz-Yazdi E, et al. PNC-27, a Chimeric p53-Penetratin Peptide, Binds HDM-2 and Induces Selective Membrane-Pore Formation and Cancer Cell Lysis. Biomedicines. 2022.
2. Michl J, et al. (Pincus MR). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding HDM-2 in their membranes. PNAS. 2010.
3. Krzesaj P, et al. (Pincus MR). PNC-27 interactions with plasma membrane-bound hdm-2 and mitochondrial membranes. Ann Clin Lab Sci. 2024.

For research use only. PNC-27 is an experimental compound studied only in vitro; not a drug and not FDA-approved; not for human or veterinary use. Bolt Peptide does not sell it. Statements have not been evaluated by the FDA.